

# ON THE GO WITH ENTYVIO



## Traveling with ENTYVIO?

Here are some quick tips.

### What is ENTYVIO® (vedolizumab)?

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis (UC).
- moderately to severely active Crohn's disease (CD).

### Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

**Please see additional Important Safety Information [page 4](#) and [5](#).**

# TIPS FOR YOUR NEXT TRIP



## Tell your specialty pharmacy about your travel plans

They can help you arrange any shipment details. Reach out to your healthcare provider or *EntyvioConnect* Nurse Educator with other questions.



## Pack your medicine and supplies in your travel cooler

This will help prevent breakage or sunlight exposure. Make sure to pack extra alcohol pads, cotton balls, and dressings in case of emergencies.

**Please see storage guidelines on the next page.**



## Bring your own sharps containers

The ENTYVIO Pen can't go in regular trash. Bring a sharps container or empty laundry detergent container so you can safely dispose of your pen after injection. Find more information about disposing used sharps at [SafeNeedleDisposal.org](http://SafeNeedleDisposal.org).



## Know airport security requirements

Keep your self-injection pen in your carry-on. Frozen liquid items and gel packs are allowed in your carry-on as long as they are frozen solid when presented for screening. If frozen liquid items are partially melted, slushy, or have any liquid at the bottom of the container, they must be 3.4 ounces or smaller.

**Note: Do not freeze your ENTYVIO Pen or use the pen if it has been frozen.**



## Carry your prescription with you

A digital or print version of your prescription may help respond to questions you may receive about the purpose of your medication.

## Handling and storing ENTYVIO

Once you arrive, remove the ENTYVIO Pen from the travel cooler and place it in a refrigerator.

- Store your pen in the refrigerator between 36°F to 46°F (2°C to 8°C)
- Your pen can be left in its box at room temperature up to 77°F (25°C) for **up to 7 days**
- Do not use if left out of the refrigerator for more than 7 days, if the pen has been frozen, or left in direct sunlight
- If you miss a dose, inject ENTYVIO as soon as you are able

## Got questions about traveling with ENTYVIO?

Reach out to your healthcare provider or *EntyvioConnect* Nurse Educator.

For full details about injecting ENTYVIO, talk with your healthcare provider and see the [Instructions for Use](#) included in this kit.

## Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see additional Important Safety Information on [page 4 and 5](#).

## Important Safety Information for ENTYVIO® (vedolizumab)

- **Do not receive ENTYVIO if you** have had an allergic reaction to ENTYVIO or any of its ingredients.
- **ENTYVIO may cause serious side effects, including:**
  - **Infusion-related and serious allergic reactions** can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
  - **Infections.** ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
  - **Progressive Multifocal Leukoencephalopathy (PML).** People with weakened immune systems can get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). Although unlikely while receiving ENTYVIO, a risk of PML cannot be ruled out. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
  - **Liver problems** can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).
- **The most common side effects of ENTYVIO include:** common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, pain in extremities, and with injections under the skin: pain, swelling, itching, hives, bruising, rash, or redness at the injection site. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.

## Important Safety Information (cont'd)

- **Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you:** have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.
- **Tell your healthcare provider about all the medicines you take, especially if you take or have recently taken** Tysabri (natalizumab), Tyruko (natalizumab-sztn), a Tumor Necrosis Factor (TNF) blocker medicine, a medicine that weakens your immune system (immunosuppressant), or corticosteroid medicine.

**Please see accompanying full [Prescribing Information](#), including the [Medication Guide](#), for ENTYVIO and talk with your healthcare provider.**

**ENTYVIO is available for:**

- **intravenous (IV) infusion: 300 mg vedolizumab.**
- **subcutaneous (SC) injection: 108 mg vedolizumab.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

### What is ENTYVIO?

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis (UC).
- moderately to severely active Crohn's disease (CD).

It is not known if ENTYVIO is safe and effective in children under 18 years of age.



## **Want a refresher course on how to inject ENTYVIO?**

**Visit [ENTYVIO.com/how-to](https://www.entyvio.com/how-to) to watch  
a video about injecting ENTYVIO.**

### **Safety Considerations with ENTYVIO**

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

**Please see additional Important Safety Information [page 4 and 5](#).**



©2024 Takeda Pharmaceuticals U.S.A., Inc. 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. ENTYVIO and the ENTYVIO logo are registered trademarks of Millennium Pharmaceuticals, Inc. US-VED-3022v1.0 04/24